Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Receivables (2016 - 2025)

Sanofi's Receivables history spans 11 years, with the latest figure at $11.5 billion for Q4 2025.

  • For Q4 2025, Receivables rose 18.09% year-over-year to $11.5 billion; the TTM value through Dec 2025 reached $11.5 billion, up 18.09%, while the annual FY2025 figure was $11.2 billion, 13.16% up from the prior year.
  • Receivables for Q4 2025 was $11.5 billion at Sanofi, up from $9.7 billion in the prior quarter.
  • Across five years, Receivables topped out at $11.5 billion in Q4 2025 and bottomed at $9.6 billion in Q4 2021.
  • The 5-year median for Receivables is $9.9 billion (2022), against an average of $10.3 billion.
  • The largest annual shift saw Receivables decreased 8.3% in 2024 before it grew 18.09% in 2025.
  • A 5-year view of Receivables shows it stood at $9.6 billion in 2021, then increased by 3.46% to $9.9 billion in 2022, then rose by 7.28% to $10.6 billion in 2023, then fell by 8.3% to $9.7 billion in 2024, then rose by 18.09% to $11.5 billion in 2025.
  • Per Business Quant, the three most recent readings for SNY's Receivables are $11.5 billion (Q4 2025), $9.7 billion (Q4 2024), and $10.6 billion (Q4 2023).